drugset
drugset / Trial / NCT04136366

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

NCT04136366 ↗

Phase 3 Completed 106 enrolled Aldeyra Therapeutics, Inc.
RandomizedParallel-groupOpen-labelPrevention

Summary

The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.

Timeline

Start
2019-11-15
Primary completion
2022-06-14
Completion
2022-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 0.8 % Other

Indications

proliferative vitreoretinopathy